Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
FBIO logo FBIO
Upturn stock ratingUpturn stock rating
FBIO logo

Fortress Biotech Inc (FBIO)

Upturn stock ratingUpturn stock rating
$1.84
Last Close (24-hour delay)
Profit since last BUY0.55%
upturn advisory
Consider higher Upturn Star rating
BUY since 31 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/16/2025: FBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $10

1 Year Target Price $10

Analysts Price Target For last 52 week
$10Target price
Low$1.33
Current$1.84
high$2.89

Analysis of Past Performance

Type Stock
Historic Profit -74.7%
Avg. Invested days 15
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/16/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 53.82M USD
Price to earnings Ratio -
1Y Target Price 10
Price to earnings Ratio -
1Y Target Price 10
Volume (30-day avg) 2
Beta 1.77
52 Weeks Range 1.33 - 2.89
Updated Date 06/30/2025
52 Weeks Range 1.33 - 2.89
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.13

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -71.24%
Operating Margin (TTM) -169.85%

Management Effectiveness

Return on Assets (TTM) -32.37%
Return on Equity (TTM) -746.25%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 36421555
Price to Sales(TTM) 0.93
Enterprise Value 36421555
Price to Sales(TTM) 0.93
Enterprise Value to Revenue 0.63
Enterprise Value to EBITDA -0.29
Shares Outstanding 29569900
Shares Floating 21991150
Shares Outstanding 29569900
Shares Floating 21991150
Percent Insiders 21.11
Percent Institutions 16.61

Analyst Ratings

Rating 2
Target Price 10
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Fortress Biotech Inc

stock logo

Company Overview

overview logo History and Background

Fortress Biotech Inc. was founded in 2006. It operates as a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products, particularly in the areas of oncology, dermatology, and rare diseases.

business area logo Core Business Areas

  • Drug Development and Commercialization: Focused on developing and commercializing pharmaceutical products, including prescription drugs.
  • Subsidiary Management: Fortress Biotech manages a portfolio of subsidiary companies, each focused on specific therapeutic areas or technologies. These subsidiaries include Avenue Therapeutics, Cyprium Therapeutics, and Checkpoint Therapeutics.

leadership logo Leadership and Structure

Lindsay A. Rosenwald, M.D. serves as Chairman, President, and Chief Executive Officer. The company operates with a decentralized structure, with individual subsidiaries managed by their own leadership teams but overseen by Fortress Biotech's corporate management.

Top Products and Market Share

overview logo Key Offerings

  • Accutane (isotretinoin): A treatment for severe acne. Fortress markets it through its subsidiary, Journey Medical Corporation. While precise market share data for Journey Medical's specific product offerings isn't readily available, the acne treatment market is competitive, with key players including Sun Pharmaceutical and Teva Pharmaceutical Industries.
  • Cosibelimab: Checkpoint Therapeutics, a subsidiary of Fortress Biotech, is developing cosibelimab, an anti-PD-L1 antibody for the treatment of various cancers. If approved, it would compete with established PD-1/PD-L1 inhibitors from companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and long development timelines. It is a growing market driven by aging populations and increasing healthcare spending.

Positioning

Fortress Biotech positions itself as an incubator and accelerator of promising drug candidates and technologies. Its competitive advantage lies in its ability to acquire and develop undervalued assets, leveraging its network and expertise.

Total Addressable Market (TAM)

The pharmaceutical market is expected to reach trillions of dollars. Fortress Biotech is positioned to capture a share of this TAM through its pipeline of product candidates and commercialized products.

Upturn SWOT Analysis

Strengths

  • Diversified portfolio of subsidiaries
  • Experienced management team
  • Focus on acquiring and developing undervalued assets
  • Strategic partnerships

Weaknesses

  • Dependence on subsidiaries' success
  • High R&D costs
  • Reliance on external funding
  • History of operating losses

Opportunities

  • Acquisition of new assets
  • Expansion into new therapeutic areas
  • Regulatory approvals for pipeline products
  • Strategic alliances

Threats

  • Regulatory risks
  • Competition from larger pharmaceutical companies
  • Patent expirations
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • BMY
  • LLY
  • PFE
  • SUNPHARMA.BO

Competitive Landscape

Fortress Biotech faces intense competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. Its success depends on its ability to identify and develop niche products and effectively manage its subsidiary companies.

Major Acquisitions

Avenue Therapeutics

  • Year: 2013
  • Acquisition Price (USD millions): 17
  • Strategic Rationale: To acquire a late-stage company with a lead product candidate, IV Tramadol, for the treatment of acute post-operative pain. It allowed Fortress to expand its portfolio into pain management.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been uneven, driven by acquisitions and product development milestones. Profitability has been a challenge.

Future Projections: Future growth depends on the success of pipeline products, strategic acquisitions, and commercialization efforts.

Recent Initiatives: Recent initiatives include advancing clinical trials for key drug candidates and exploring strategic partnerships.

Summary

Fortress Biotech operates as an incubator for biopharmaceutical companies, facing high R&D costs. Its decentralized structure allows specialized focus but relies on subsidiary success. Growth depends on pipeline progress and strategic acquisitions. Competitors are much larger and pose a significant threat. Its overall performance should be classified as weak.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (SEC)
  • Company Website
  • Market Research Reports
  • Financial News Sources

Disclaimers:

The information provided is for informational purposes only and should not be construed as financial advice. Market share and financial data are estimates and may vary. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Fortress Biotech Inc

Exchange NASDAQ
Headquaters Bay Harbor Islands, FL, United States
IPO Launch date 2011-11-17
Executive Chairman, President & CEO Dr. Lindsay Allan Rosenwald M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 101
Full time employees 101

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.